Hikma Pharmaceuticals PLC (HIK) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded.

Total Assets Chart for Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC (HIK) total assets for FY2025 were GBP 5.7B, a 10.5% change from FY2024. Hikma Pharmaceuticals PLC's total assets grew from GBP 94.9M in 2002 to GBP 5.7B in 2025 (5880.3% over 23 years). Total assets compound annual growth rate: 5-year CAGR of 6.5%, 10-year CAGR of 8.1%, 20-year CAGR of 14.2%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (British Pounds)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
£3.40B
Implied Share Price
£16.41
Enterprise Value
£4.62B
Revenue (TTM)
£3.42B
EBITDA
£879.00M
Profit Margin
11.32%
Trailing P/E
12.72
Forward P/E
9.70
Price/Book (MRQ)
1.84
Price/Sales (TTM)
0.99
EV/EBITDA
7.29
EV/Revenue
1.84
Dividend Yield
5.24%
Book Value
£8.54
Free Cash Flow (FY2025)
£165.40M
Free Cash Flow Yield
4.87%

Snapshot as of 27th August 2026 — not point-in-time controlled, may lag the live market by a few days.